We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly and Incyte’s new once-daily rheumatoid arthritis drug baricitinib outperformed the standard care in a Phase 3 clinical trial, putting the drugmakers on track for a regulatory filing this year. Read More
With a growing number of biologics set to lose patent protection in coming years, a leading industry group is calling for regulatory reforms to encourage the development and approval of biosimilars. Read More
New Hampshire’s attorney general is investigating whether some opioid manufacturers knowingly misled doctors and patients about their drugs’ safety and benefits, causing the state to pay for potentially dangerous and unnecessary opioid prescriptions. Read More
President Barack Obama late Wednesday was expected to sign a measure to fund the federal government at fiscal year 2015 levels through Dec. 11, thereby averting a government shutdown. Read More